Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Gusacitinib
Therapeutic Area : Undisclosed
Study Phase : Preclinical
Sponsor : Sanofi
Deal Size : $627.6 million
Deal Type : Licensing Agreement
Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor
Details : Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi. Sanofi will explore its potential in a new indication not previously studied through a phase 1 study.
Product Name : ASN-002
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 23, 2025
Lead Product(s) : Gusacitinib
Therapeutic Area : Undisclosed
Highest Development Status : Preclinical
Sponsor : Sanofi
Deal Size : $627.6 million
Deal Type : Licensing Agreement
Lead Product(s) : ASN008
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Sanofi
Deal Size : $372.0 million
Deal Type : Series D Financing
Formation Bio Raises Series D to Expand Drug Pipeline and AI-Driven Development Platform
Details : The fund aims to advance the pipeline, which includes the company lead product ASN008, a sodium channel blocker. Currently, it is being evaluated for the treatment of atopic dermatitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 26, 2024
Lead Product(s) : ASN008
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Sanofi
Deal Size : $372.0 million
Deal Type : Series D Financing
Lead Product(s) : AVID200
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 08, 2019
Lead Product(s) : AVID200
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AVID100
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AVID100 in Advanced Epithelial Carcinomas
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 29, 2017
Lead Product(s) : AVID100
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
